Computed Tomography-based Radiomics Nomogram for Predicting Therapeutic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer : A Scale for Treatment Predicting

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Mar 12

PMID 38467894

Authors

Wenjing Chen

Weiteng Zhang

Xietao Chen

Weisong Dong

YiQi Cai

Jun Cheng

Jinji Jin

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Neoadjuvant chemotherapy results in various responses when used to treat locally advanced gastric cancer, we aimed to develop and validate a predictive model of the response to neoadjuvant chemotherapy in patients with gastric cancer.

Methods: A total of 128 patients with locally advanced gastric cancer who underwent pre-treatment computed tomography (CT) scanning followed by neoadjuvant chemoradiotherapy were included (training cohort: n = 64; validation cohort: n = 64). We built a radiomics score combined with laboratory parameters to create a nomogram for predicting the efficacy of neoadjuvant chemotherapy and calculating scores for risk factors.

Results: The radiomics score system demonstrated good stability and prediction performance for the response to neoadjuvant chemotherapy, with the area under the curve of the training and validation cohorts being 0.8 and 0.64, respectively. The radiomics score proved to be an independent risk factor affecting the efficacy of neoadjuvant chemotherapy. In addition to the radiomics score, four other risk factors were included in the nomogram, namely the platelet-to-lymphocyte ratio, total bilirubin, ALT/AST, and CA199. The model had a C-index of 0.8.

Conclusions: Our results indicated that radiomics features could be potential biomarkers for the early prediction of the response to neoadjuvant treatment.

Citing Articles

Application and progress of nomograms in gastric cancer.

Wang H, Ding Y, Zhuang M, Li K, Zhao S, Li D Front Med (Lausanne). 2025; 12:1510742.

PMID: 39944483 PMC: 11813919. DOI: 10.3389/fmed.2025.1510742.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Imamura H, Takiguchi S, Yamamoto K, Hirao M, Fujita J, Miyashiro I . Morbidity and mortality results from a prospective randomized controlled trial comparing Billroth I and Roux-en-Y reconstructive procedures after distal gastrectomy for gastric cancer. World J Surg. 2012; 36(3):632-7. DOI: 10.1007/s00268-011-1408-9. View

Takahashi T, Saikawa Y, Kitagawa Y . Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013; 5(1):48-63. PMC: 3730304. DOI: 10.3390/cancers5010048. View

Ychou M, Boige V, Pignon J, Conroy T, Bouche O, Lebreton G . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715-21. DOI: 10.1200/JCO.2010.33.0597. View

Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T . Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017; 28(8):1876-1881. DOI: 10.1093/annonc/mdx236. View

Al-Batran S, Homann N, Pauligk C, Illerhaus G, Martens U, Stoehlmacher J . Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017; 3(9):1237-1244. PMC: 5824287. DOI: 10.1001/jamaoncol.2017.0515. View

Xiong B, Cheng Y, Ma L, Zhang C . An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest. 2014; 32(6):272-84. DOI: 10.3109/07357907.2014.911877. View

Proctor M, Horgan P, Talwar D, Fletcher C, Morrison D, McMillan D . Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study. Cancer. 2013; 119(12):2325-32. DOI: 10.1002/cncr.28018. View

Dong D, Tang L, Li Z, Fang M, Gao J, Shan X . Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019; 30(3):431-438. PMC: 6442651. DOI: 10.1093/annonc/mdz001. View

10.

Zhang W, Fang M, Dong D, Wang X, Ke X, Zhang L . Development and validation of a CT-based radiomic nomogram for preoperative prediction of early recurrence in advanced gastric cancer. Radiother Oncol. 2019; 145:13-20. DOI: 10.1016/j.radonc.2019.11.023. View

11.

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

12.

Lambin P, Leijenaar R, Deist T, Peerlings J, de Jong E, van Timmeren J . Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017; 14(12):749-762. DOI: 10.1038/nrclinonc.2017.141. View

13.

Lubner M, Smith A, Sandrasegaran K, Sahani D, Pickhardt P . CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges. Radiographics. 2017; 37(5):1483-1503. DOI: 10.1148/rg.2017170056. View

14.

Ryan R, Gibbons D, Hyland J, Treanor D, White A, Mulcahy H . Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005; 47(2):141-6. DOI: 10.1111/j.1365-2559.2005.02176.x. View

15.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

16.

Davnall F, Yip C, Ljungqvist G, Selmi M, Ng F, Sanghera B . Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. Insights Imaging. 2012; 3(6):573-89. PMC: 3505569. DOI: 10.1007/s13244-012-0196-6. View

17.

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P . Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4):441-6. PMC: 4533986. DOI: 10.1016/j.ejca.2011.11.036. View

18.

Jackson A, OConnor J, Parker G, Jayson G . Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007; 13(12):3449-59. DOI: 10.1158/1078-0432.CCR-07-0238. View

19.

Ellingson B . Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. Curr Neurol Neurosci Rep. 2014; 15(1):506. DOI: 10.1007/s11910-014-0506-0. View

20.

Mazurowski M . Radiogenomics: what it is and why it is important. J Am Coll Radiol. 2015; 12(8):862-6. DOI: 10.1016/j.jacr.2015.04.019. View